TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma, Medulloblastoma, Relapse

In brief

The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma both alone and in combination with temozolomide (a currently approved drug). An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the safety and tolerability of TPI 287 both alone and in combination with temozolomide, and look to establish a safe dose of this agent. The study will also look at the tumor's response to these drugs, but this is not the primary objective of this study. TPI 287 was shown to be effective in stopping tumor growth and was also shown to be safe in three different animal species. TPI 287 has been tested in humans in four clinical trials, and approximately 100 subjects with various types of cancers have received the drug. All of these subjects that have received TPI 287 have been adults. TPI 287 has not been tested in a pediatric population before this study. Temozolomide was tested in recurrent neuroblastoma and showed activity in a recently published study. Preclinical studies of TPI in combination with temozolomide have shown at minimum an additive effect. The ability of temozolomide and TPI 287 to be effective in combination is suggested by these two drugs showing even greater activity when used together.

Key facts

Study ID: NCT00867568
Run by: Giselle Sholler
People needed: 18
Starts: 2009-03-01
Expected to finish: 2016-02-01
Last updated by the study team: 2024-08-06

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have histologically proven neuroblastoma and confirmation of refractory or recurrent disease or medulloblastoma with histologic confirmation at diagnosis or at the time of recurrence/progression
Patients must be age >12 months and diagnosed before the age of 21
Life expectancy must be more than 3 months
If measurable disease, this must be demonstrated by residual abnormal tissue at a primary or metastatic site measuring more than 1 cm in any dimension by standardized imaging (CT or MRI). For patients with neuroblastoma who only have skeletal disease, there must be at least two persisting skeletal foci on meta-iodobenzylguanidine (MIBG) follow-up scans
Current disease state must be one for which there is currently no known curative therapy
Lansky Play Score must be more than 30 and/or ECOG performance status must be 0 to 2
For patients with medulloblastoma receiving steroids, the dose must be stable (i.e. not increasing) for at least one week before starting study
Patients without bone marrow metastases must have an ANC > 750/μl and platelet count >50,000/μl
Adequate liver function must be demonstrated, defined as:
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND
SGPT (ALT) < 10 x upper limit of normal (ULN) for age
No other significant organ toxicity defined as > Grade 2 by National Cancer Institute Common Toxicity Criteria for Adverse Events version 3 (NCI-CTCAE V3.0 (http://ctep.cancer.gov/forms/CTCAEv3.pdf))
A negative urine pregnancy test is required for female participants of child bearing potential (≥13 years of age or after the onset of menses)
Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these can not be used, contraceptive foam with a condom is recommended
Informed Consent: All patients and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
Patients may have received microtubulin inhibitors and/or temozolomide during previous therapies

You may not qualify if…

Patients who have received any chemotherapy administered within the last 21 days
Patients who have received radiotherapy within the last 30 days
Patients who have received myeloablative therapy within the previous 3 months
Patients receiving anti-tumor therapy for their disease or any investigational drug concurrently
Patients with serious infection or a life-threatening illness (unrelated to tumor) that is > Grade 2 (NCI CTCAE V3.0), or active, serious infections requiring parenteral antibiotic therapy within 4 weeks prior to screening
Any other medical condition, including malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a patient's ability to sign or the legal guardian's ability to sign the informed consent, and patient's ability to cooperate and participate in the study
Patients with known hypersensitivity to any of the components of the drugs to be administered on study
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study

Where it is running

Rady Children's Hospital — San Diego, California, United States
Arnold Palmer Hospital for Children- MD Anderson — Orlando, Florida, United States
Cardinal Glennon Children's Medical Center — St Louis, Missouri, United States
Levine Children's Hospital — Charlotte, North Carolina, United States
Medical University of South Carolina — Charleston, South Carolina, United States
UVM/FAHC — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.